Background {#Sec1}
==========

*Staphylococcus aureus* (*S. aureus*) is a well-known cause of infection and can lead to serious adverse health outcomes including mortality. Asymptomatic colonization by *S. aureus* greatly increases risk of infection \[[@CR1]--[@CR3]\]. The nares are the primary site of *S. aureus* colonization, however, *S. aureus* has also been found to colonize the gastrointestinal (GI) tract, oropharynx, and axillae of many individuals \[[@CR4]--[@CR6]\]. Those colonized by methicillin-resistant *S. aureus* (MRSA) are at even greater risk of subsequent infection than those colonized with methicillin-susceptible *S. aureus* (MSSA) \[[@CR3], [@CR7]\]. Thus reducing carriage of *S. aureus* is an important mitigating step in preventing infection.

Current treatment options for MRSA are limited to strong antibiotics that are accompanied by severe side effects and promote antibiotic resistance \[[@CR8], [@CR9]\]. Little is known about other *S. aureus* decolonization methods, however probiotics are emerging as a potentially low cost, well tolerated, and inexpensive alternative \[[@CR10]--[@CR14]\]. Probiotics are cultures of live bacteria species that normally reside in the human gut. They can help prevent infections by pathogens by outcompeting pathogenic bacteria for essential nutrients and mucosal binding sites, as well as enhancing immune function and promoting the production of mucosal and epithelial barriers \[[@CR15]\]. *Lactobacillus rhamnosus* (*L. rhamnosus*) HN001, in particular has been shown to improve both innate and acquired immune function in multiple studies against a variety of bacterial infection threats \[[@CR12], [@CR13], [@CR16]--[@CR19]\]. It has been chosen for use in this study due to its immune effects and its safety and tolerability \[[@CR20]--[@CR22]\].

Given the paucity of data on the clinical use of probiotics to reduce *S. aureus* colonization \[[@CR23]\], a randomized, double blind, phase II clinical trial was undertaken to evaluate the effect of probiotic use on *S. aureus* carriage. We hypothesized that the use of *L. rhamnosus* HN001, when compared to placebo, would decrease GI and extra-GI colonization by *S. aureus*, over a 4-week period.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The full protocol for this study has been previously published \[[@CR24]\]. Study procedures and written consent form were approved by the University of Wisconsin Institutional Review Board and the Veterans Affairs Research and Development Committee. A total of 113 subjects were recruited from the William S. Middleton Veterans Affairs Medical Center in Madison, WI, and screened for *S. aureus* colonization at several body sites (Week 0). At the first study visit (Day 0, Week 1) subjects were stratified by site of colonization at baseline, either GI or extra-GI, and randomized into the probiotic or placebo groups. Those whose oropharyngeal, or perirectal swab tested positive for *S. aureus* via real-time polymerase chain reaction (PCR) assay only at baseline were included in the GI group. Those who tested negative for GI sites, and had at least one positive result from nasal, axillary, or wound swabs were included in the extra-GI group. Stratification assignment was based solely on PCR results, not results of the culture assays that were also performed. The first blood and stool samples were also collected at this visit. Contact with subjects was made weekly to collect adherence and adverse events data, as well a stool sample at the end of Weeks 1, 2, and 3. At the second study visit (Week 4), patients were re-screened for *S. aureus* using nasal, oropharyngeal, axillary, and wound swabs. Final stool and blood samples were also collected at Week 4. Presence of *S. aureus* and *L. rhamnosus* in stool was assessed at each of these time points. Participant compliance and adverse events were self-reported weekly throughout the study. Non-compliance was defined as missing at least one medication dose during the duration of the study.

Enrollment criteria {#Sec4}
-------------------

Participants were eligible to enroll if they screened positive for *S. aureus* colonization, were at least 18 years of age, could take oral medication, and could consent to participation. A variety of exclusion criteria were used, including current MRSA decolonization or treatment regimens. A full list of inclusion and exclusion criteria are listed in the protocol \[[@CR24]\].

Intervention {#Sec5}
------------

The intervention consisted of once daily oral probiotic or placebo capsule administered for four weeks. The probiotic capsule contained 1 × 10^10^ colony forming units of *L. rhamnosus HN001* and an inert filler. Placebo capsules were identical in appearance and taste, but contained only the inert fuller. Probiotic and placebo capsules were provided by DuPont Nutrition and Health, Madison, WI.

Microbiological analysis {#Sec6}
------------------------

Swabs and stool samples were analyzed for the presence of MSSA and MRSA using a real-time PCR assay, GeneXpert's Xpert SA Nasal Complete kit (Cepheid, Sunnyvale CA), as well as traditional selective culture methods \[[@CR25]\]. Cultures were grown using broth enrichment followed by standard microbiologic techniques including inoculation of selective media and identification of colony morphology \[[@CR26]\]. Kirby Bauer Disk Diffusion testing was used to assess resistance to oxacillin \[[@CR27], [@CR28]\]. Stool samples were analyzed for the presence of *L. rhamnosus* HN001 using traditional culture methods followed by a strain specific in-house PCR.

Statistical analysis {#Sec7}
--------------------

To assess demographics and adverse events, frequency tables with Fisher's exact test were used to account for small cell sizes. To make results of this trial more generalizable to a broader population, and more useful for practitioners, data was analyzed by intention to treat. To assess the effect of 4 weeks of treatment on colonization by *S. aureus*, comparing probiotic and placebo groups, the Cochran-Mantel-Haenszel test for differences across strata was used, stratifying by baseline carriage site (GI or extra-GI). All data analysis was conducted in SAS version 9.4 (SAS Institute, Cary NC).

Results {#Sec8}
=======

The study population was predominantly male, with an overall average age of 63.6 years old (Table [1](#Tab1){ref-type="table"}). The study groups had similar medical histories, although the placebo group had a higher frequency of current liver disease than the probiotic group (Table [1](#Tab1){ref-type="table"}). At baseline, 80% of patients were colonized at more than one sampling site. The large frequency of participants in the GI randomization group who were colonized at axillary/groin, nasal, and wound sites show that many participants were colonized at both GI and extra-GI sites (Fig. [1](#Fig1){ref-type="fig"}).Table 1Distribution of demographics and medical conditions of study participants, stratified by treatment groupProbiotic (*N* = 52)\
n (%)Placebo (*N* = 61)\
n (%)*P*-valueAge (mean), (Q1, Q2)64.4 (55.5, 69)62.9 (57, 68)0.7322Gender (Male)49 (94.2)56 (91.8)0.7239Ambulatory Status (Inpatient)4 (7.7)3 (4.9)0.5633Regular Probiotic Use^a^17 (32.7)22 (36.1)0.8429History of *C. difficile* Infection1 (1.9)1 (1.6)1.0000History of Gram Negative Bacilli Infection5 (9.6)9 (14.8)0.5686History of MRSA Infection15 (28.9)12 (19.7)0.2763History of MSSA Infection3 (5.8)5 (8.2)0.7239History of VRE Infection0 (0.0)0 (0.0)1.0000History of Candida Infection3 (5.8)1 (1.6)0.3325Ongoing Clinical Infection of Any Type1 (1.9)2 (3.3)1.0000Human Immunodeficiency Virus Infection1 (1.9)1 (1.6)1.0000Current Active Surgical Wound4 (7.7)2 (3.3)0.4113Current Active Cancer2 (3.9)2 (3.3)0.5780Current Coronary Artery Disease23 (44.2)22 (36.1)0.5018Current Diabetes17 (32.7)22 (36.1)0.8429Current Insulin Requirement for Diabetes7 (13.5)8 (13.1)1.0000Current Gastrointestinal Disease27 (51.9)30 (49.2)0.9202Current Hemodialysis0 (0.0)1 (1.6)1.0000Current Liver Disease3 (5.8)13 (21.3)0.0282Current Lung Disease18 (34.6)16 (26.2)0.4114Current Neutropenia0 (0.0)1 (1.6)1.0000Current Open Wound2 (3.9)2 (3.3)0.6650Current Peripheral Vascular Disease7 (13.5)8 (13.1)1.0000Current Renal Failure2 (3.9)3 (4.9)1.0000Current Skin Condition14 (26.9)11 (18.0)0.2672Current Alcohol or Drug Abuse3 (5.8)1 (1.6)0.3325Current Smoker10 (19.2)14 (23.0)0.7040*Abbreviations*: *Q* quartile, *C.* clostridium, *MRSA* methicillin-resistant *Staphylococcus aureus*, *MSSA* methicillin susceptible *Staphylococcus aureus*, *VRE* vancomycin resistant Enterococci^a^This category includes all types of probiotics, and yogurts that may or may not include probioticsFig. 1Percent frequency of methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin susceptible *S. aureus* (MSSA), and total combined *S. aureus* (SA) colonization at endpoint and baseline of the probiotic and placebo groups within the gastrointestinal (GI) (**a**) and extra-GI (**b**) strata. Results shown are from both polymerase chain reaction (PCR) assays, and culture assays. **a** *Staphylococcus aureus* Colonization at Baseline and Endpoint in GI Group. **b***Staphylococcus aureus* Colonization at Baseline and Endpoint in Extra-GI Group

One participant was lost to follow-up and none withdrew from the study (Table [2](#Tab2){ref-type="table"}). Rates of non-compliance were similar among the study groups, although they were slightly higher in the placebo group. Although the frequency of missing a single treatment dose was relatively high in both groups, only one participant missed more than 25% of study doses. The self-reported use of probiotic products other than the trial drug was similar between treatment groups. Detection by PCR found that no subject in any treatment arm was colonized at baseline with *L. rhamnosus* HN001. At week 4, 51.9% of the probiotic group, and 1.6% of the placebo group were colonized with *L. rhamnosus* HN001. There were no significant differences in adverse events between the probiotic and placebo groups (Table [2](#Tab2){ref-type="table"}). Overall, bowel function was the most common adverse event experienced in both treatment groups. Those in the GI group experienced more muscle cramping than the extra-GI group.Table 2Frequencies of study compliance and adverse events stratified by baseline colonization site and randomized treatment groupComplianceExtra-GI (*N* = 50)GI (*N* = 63)Probiotic (*N* = 18)\
n (%)Placebo (*N* = 32)\
n (%)P-valueProbiotic (*N* = 34)\
n (%)Placebo (*N* = 29)\
n (%)*P*-valueWithdrawal/Lost to Follow-Up0 (0.0)1 (3.1)1.00000 (0.0)0 (0.0)1.0000Non-Compliant3 (16.7)7 (21.9)0.71899 (26.5)9 (31.0)0.6699Other Probiotic Use7 (38.9)11 (34.4)0.578811 (32.4)10 (34.5)0.8418Adverse Events Fever0 (0.0)2 (6.3)0.51051 (2.9)1 (3.5)1.0000 Infection0 (0.0)1 (3.1)1.00001 (2.9)0 (0.0)1.0000 Nausea/Vomiting3 (16.7)5 (15.6)1.00004 (11.8)2 (6.9)0.6782 Constipation4 (22.2)2 (6.3)0.17100 (0.0)1 (3.5)0.4603 Cough/Cold/Congestion1 (5.6)5 (15.6)0.39913 (8.8)6 (20.7)0.2804 Headache0 (0.0)1 (3.1)1.00001 (2.9)1 (3.5)1.0000 Muscle Pain/Cramp/Spasm3 (16.7)5 (15.6)1.000011 (32.4)4 (13.8)0.1371 Upset Stomach/Heartburn1 (5.6)1 (3.1)1.00001 (2.9)1 (3.5)1.0000 Gas/Bloating2 (11.1)1 (3.1)0.29141 (2.9)1 (3.5)1.0000 Insomnia0 (0.0)0 (0.0)1.00001 (2.9)1 (3.5)1.0000 Unusual Stool (Loose/ Discolored/More Frequent)2 (11.1)8 (25.0)0.29477 (20.6)5 (17.2)1.0000 Bad Taste0 (0.0)2 (6.3)0.52980 (0.0)1 (3.5)0.4603 Cardiovascular Event0 (0.0)2 (6.3)0.52980 (0.0)0 (0.0)1.0000 Itchiness0 (0.0)0 (0.0)1.00000 (0.0)2 (6.9)0.2079 Swelling1 (0.0)1 (3.1)1.00000 (0.0)0 (0.0)1.0000*Abbreviations*: *GI* gastrointestinal

The prevalence of MRSA, MSSA, and any *S. aureus* in stool samples collected at the end of weeks 1, 2, and 3 were similar between the placebo and probiotic groups each week (data not shown). Stool sample colonization by MSSA and total *S. aureus* (combined MSSA and MRSA) prevalence of those initially only colonized at extra-GI sites was lower in the probiotic than placebo group by more than 15%, (Fig. [1](#Fig1){ref-type="fig"}). It is also notable that there was an approximately 30% reduction in nasal colonization by MSSA in the extra-GI placebo group between baseline and week 4 (Fig. [1](#Fig1){ref-type="fig"}). The odds ratio, adjusted for original colonization site, estimates that those in the probiotic group had 73% lower odds of MSSA presence, and 83% lower odds of any *S. aureus* presence in the stool sample at endpoint, as those in the placebo group (Fig. [2](#Fig2){ref-type="fig"}). No other sampling sites showed a significant difference in endpoint colonization between the probiotic and placebo groups (Fig. [2](#Fig2){ref-type="fig"}). When sampling sites were pooled and analyzed in categories of GI or extra-GI, there were no significant differences between probiotic and placebo groups (Table [3](#Tab3){ref-type="table"}).Fig. 2Cochran-Mantel-Haenszel odds ratios of methicillin-resistant *Staphylococcus aureus* (MRSA), methicillin susceptible *S. aureus* (MSSA), and total combined *S. aureus* (SA) colonization at different body sites, stratified by initial colonization site, either gastrointestinal (GI), or extra-GI, comparing the probiotic group to the placebo groupTable 3Frequencies of MRSA, MSSA, and Total SA colonization at Week 4 by GI and extra-GI body site, stratified by site of original colonization, and randomized treatment groupInitial Colonization Site:Extra-GI (*N* = 50)GI (*N* = 63)Cochran-Mantel-HaenszelFinal Colonization SiteOrganismProbiotic (*N* = 18) n (%)Placebo (*N* = 32) n (%)P-valueProbiotic (*N* = 34) n (%)Placebo (*N* = 29) n (%)P-valueOdds Ratio95% Confidence IntervalGIMRSA1 (5.6)2 (6.3)1.00005 (14.7)4 (13.8)1.00001.000.29--3.43MSSA9 (50.0)16 (50.0)0.836823 (67.7)21 (72.4)0.91050.780.34--1.83SA Total9 (50.0)17 (53.1)0.758825 (73.5)24 (82.8)0.75740.620.26--1.52Extra-GIMRSA3 (16.7)3 (9.4)0.44855 (14.7)4 (13.8)1.00001.300.43--3.90MSSA15 (83.3)19 (59.4)0.133216 (47.1)16 (55.2)0.86351.110.49--2.53SA Total16 (88.9)22 (68.8)0.272820 (58.8)19 (65.5)0.61341.080.46--2.52*Abbreviations*: *MRSA* methicillin-resistant *Staphylococcus aureus*, *MSSA* methicillin susceptible *Staphylococcus aureus*, *SA Staphylococcus aureus*, *GI* gastrointestinal

Because the original stratification of treatment was done using only PCR colonization results, some participants were stratified to the extra-GI group, but had positive cultures at GI sites. We undertook a sensitivity analysis in which we re-categorized these subjects by initial colonization site based on all swab and stool samples analyzed by both culture and PCR (instead of just by PCR). Twenty participants (10 placebo, 10 probiotic) originally included in the extra-GI randomization strata were moved to the GI strata in this analysis. While effect sizes of the odds ratios were similar to the original analysis, there was no statistical significance (Additional file [1](#MOESM1){ref-type="media"}).

Discussion {#Sec9}
==========

*S. aureus* infections are a serious health risk with limited treatment options, and those who are colonized by *S. aureus* are at much higher risk of symptomatic infection. In this study, we observed that administration of *L. rhamnosus* HN001 over a four-week period reduced the odds of colonization in the stool sample, especially for those who were originally colonized outside of the GI tract. Probiotic treatment did not, however, reduce odds of colonization at other body sites. While the probiotic was not successful at eradicating *S. aureus* colonization at all body sites, it was associated with lower odds of colonization in the GI tract, especially for those who were stratified to the extra-GI group.

The surprising result of the reduction in nasal MSSA colonization in the extra-GI placebo group is likely explained by the natural history of *S. aureus* colonization. *S. aureus* is known to colonize intermittently and its presence is dependent on a number of factors including environmental exposures and other colonizing bacteria, to name a few \[[@CR29]--[@CR31]\]. Our study did not collect daily exposure data on participants to control for these external factors, which is why the placebo-controlled arm of the study was so important.

*L. rhamnosus* HN001 is thought to work in multiple ways. The primary potential mechanism is competitive inhibition, whereby colonizing the GI tract with healthy commensal microbes prevents the colonization of pathogens by out-competing them for vital resources \[[@CR32]\]. This is likely the mechanism that led to differences in stool colonization between probiotic and placebo groups. A second potential mechanism is that *L. rhamnosus* HN001 has previously been shown to stimulate systemic immune function \[[@CR12], [@CR13], [@CR18]\], making the host immune system more capable of eliminating *S. aureus* colonization at sites throughout the body. Based on the null results from body sites examined beyond the stool sample, it is likely that the *L. rhamnosus* HN001 used in this study population did not produce enough of a systemic immune response to affect *S. aureus* colonization at sites outside the gut. Further testing of phagocytic activity in the blood samples is currently being conducted to evaluate this hypothesis.

Our results differ from those of a study conducted in 2003 by Glück and Gebbers \[[@CR14]\], which found that ingestion of *L. rhamnosus* GG, significantly reduced the occurrence of nasal carriage of potentially pathogenic bacteria. However, this discrepancy is likely due to the different strain of probiotic used in the intervention, a different delivery matrix used (yogurt/fermented milk product versus capsule), or inclusion of different *Staphylococcus* species in the outcome. There is a paucity of data on in vivo use of probiotics as a decolonization strategy for *S. aureus*, and more research is needed in this area.

This trial contributes critical knowledge to the literature about the efficacy of probiotics to reduce *S. aureus* colonization, however, it does include some limitations. Participants of this trial were drawn from the Veterans Affairs hospital system in Madison, WI. This system predominantly serves older men, thus the majority of the study sample were older men. Therefore, this sample may not be broadly generalizable to other populations.

The seven inpatients in this study were at increased risk of re-exposure to *S. aureus* during their hospital stay. It is possible these patients were cleared of their original *S. aureus* carriage, and re-colonized during the course of the trial. While stool samples were taken during the course of the intervention, no swabs of sample sites were taken between the baseline and endpoints of the trial. Thus, we cannot determine if any subjects were de-colonized and subsequently re-colonized at any of the swabbed sites between sampling. If this were the case for any of our sample, it would bias our results toward the null. The number of inpatients in each treatment group were not statistically different, therefore adjustment for ambulatory status in the analysis was not warranted. In the future, strain typing of stored isolates from stool samples can reduce this possibility of bias.

Considering that the only significant difference in health history between the treatment groups at baseline was prevalence of liver disease, we do not believe underlying health conditions affect the interpretation of trial results. Likewise, although overall non-compliance was around 30% in both treatment groups, all but one participant missed less than a quarter of the trial doses. Non-compliance with the assigned treatment would bias our results toward the null, and given the low number of doses missed by the majority of non-compliant participants, we do not believe this strongly biases the study findings. Use of other probiotics during the study may be more troublesome. Use of all possible probiotic supplements, including yogurts, capsules, etc., were considered as other probiotic use, however, we did not verify that reported probiotic supplements actually contained probiotics. The reported use of outside probiotics by approximately 1/3 of the placebo group could bias these findings toward the null by making the treatment groups more similar than otherwise expected. Future studies should carefully monitor the use of probiotics outside of study treatment.

Conclusion {#Sec10}
==========

The results of our study support the use of this probiotic strain for gut decolonization by *S. aureus*, including MRSA. Further studies are needed to replicate the findings of this study and compare probiotics with other available agents used for decolonization such as antibiotics. Other directions for future research include examining the effect of alternative probiotic bacterial strains on *S. aureus* nasal colonization.

Additional file
===============

 {#Sec11}

Additional file 1:ST1. Sensitivity analysis results: frequencies of MRSA, MSSA, and Total SA colonization at the endpoint of the trial at each body site, stratified by re-assigned GI or extra-GI colonization group based on PCR and culture screening results at baseline, and probiotic or placebo treatment group. (DOCX 110 kb)
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